Eris LifesciencesBOM:540596 +0.14%91 Pretax Margin % is 21.19% as of Mar. 2026, which is 34% below its 10-year median of 32.06. GuruFocus rates BOM:540596 with a GF Score™ of 91/100 and a GF Value™ of ₹1,646.98 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 954 Drug Manufacturers companies, Eris Lifesciences ranks better than 81.76% on this metric.
The historical rank and industry rank for Eris Lifesciences's Pretax Margin % or its related term are showing as below:
BOM:540596'
s Pretax Margin % Range Over the Past 10 Years
Min: 16.98 Med: 32.06 Max: 37.75
Current: 20.5
BOM:540596's Pretax Margin % is ranked better than 81.76% of 954
companies
in the Drug Manufacturers industry
Industry Median: 7.295
vs BOM:540596: 20.50
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Eris Lifesciences Pretax Margin % Related Terms
Eris Lifesciences Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Eris Lifesciences's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:540596 vs ZTS, UTHR: Pretax Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Eris Lifesciences's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eris Lifesciences Pretax Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Eris Lifesciences's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Eris Lifesciences's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eris Lifesciences (BOM:540596) has a Pretax Margin % of 21.19% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Eris Lifesciences and its competitors. This is 34% below median its historical median of 32.06. Over the past decade, Eris Lifesciences' Pretax Margin % has ranged from 16.98 to 37.75. According to the industry distribution chart, Eris Lifesciences ranks #174 out of 954 companies in the Drug Manufacturers industry, placing it in the top 18.2%.
Is Eris Lifesciences' Pretax Margin % too high?
Eris Lifesciences' current Pretax Margin % of 21.19% is 34% below median its 10-year median of 32.06. Over the past 10 years, this metric has ranged from a low of 16.98 to a high of 37.75. The Drug Manufacturers industry median Pretax Margin % is 7.30. Eris Lifesciences' value of 21.19% is 190.5% above this industry median. Based on the distribution chart, Eris Lifesciences ranks #174 out of 954 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Eris Lifesciences has a GF Score™ of 91/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Eris Lifesciences' Pretax Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Eris Lifesciences ranks #174 out of 954 companies for Pretax Margin %. This places Eris Lifesciences in the top 18% of its industry — outperforming the majority of peers. The industry median Pretax Margin % is 7.30. Eris Lifesciences' value of 21.19% is 190.5% above this benchmark. Historically, Eris Lifesciences' own Pretax Margin % has ranged from 16.98 to 37.75 over the past decade. While the company's 10-year median is 32.06 vs. the industry median of 7.30, Eris Lifesciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Drug Manufacturers company?
The median Pretax Margin % among Drug Manufacturers companies is 7.30, based on 954 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Eris Lifesciences's current Pretax Margin % of 21.19% is 190.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Eris Lifesciences and its competitors. For the Drug Manufacturers industry, the median Pretax Margin % is 7.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eris Lifesciences's current Pretax Margin % is 21.19%, which is 34% below median its own 10-year median of 32.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eris Lifesciences stock overvalued right now?
Based on GuruFocus' analysis, Eris Lifesciences (BOM:540596) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹1,646.98, compared to a current price of ₹1,447.25 — trading 12.1% below its estimated fair value. The current Pretax Margin % is 21.19%, which is 34% below median its 10-year median of 32.06 and 190.5% above the Drug Manufacturers industry median of 7.30. Eris Lifesciences' overall GF Score™ is 91/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Eris Lifesciences (BOM:540596), the current Pretax Margin % is 21.19% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Eris Lifesciences (BOM:540596) Overvalued in 2026?
Based on GuruFocus' analysis, Eris Lifesciences stock appears to be undervalued.
The current stock price of ₹1,447.25 is trading 12.1% below its estimated GF Value™ of ₹1,646.98.
GuruFocus considers Eris Lifesciences to be Modestly Undervalued.
Key valuation signals for BOM:540596:
Pretax Margin %: 21.19% (34% below median its 10-year median of 32.06)
GF Value™: ₹1,646.98 vs. price of ₹1,447.25 (12.1% below fair value)
Industry Position: 190.5% above the Drug Manufacturers median (#174 of 954)
No single metric tells the full story. See the BOM:540596 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Eris Lifesciences Ltd is an India-based company engaged in the manufacturing and sale of branded pharmaceutical formulations. It focuses on Lifestyle therapies such as Diabetes Care, Cardiac Care, Nutrition, Central Nervous System, and others. The company operates in a single segment that is pharmaceuticals. Some of its brands include Glimisave, Cyblex, Eritel, Atorsave and Crevast. The company works basically within India and International with the majority of revenue from India.
91GF Score
Get the complete analysis for BOM:540596
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:540596 has been successfully added to your 
